Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 14/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | BCL2 | P10415 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2389063 | 1.00 | CYP19A1 (0.62) | CYP19A1CYP3A4CYP3A5MEN1KMT2A | |
| SCHEMBL7434539 | 0.89 | CYP19A1 (0.73) | CYP19A1MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL29401865 | 0.88 | CYP19A1 (0.85) | CYP19A1CYP3A4CYP3A5 | |
| SCHEMBL11511851 | 0.87 | TSHR (0.61) | CYP19A1MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL2864477 | 0.87 | TSHR (0.61) | CYP19A1MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL9050608 | 0.87 | CYP19A1 (0.54) | CYP19A1CYP3A4KMT2ATSHRHIF1A | |
| Triphenylmethanol SCHEMBL456603 | 0.84 | CYP19A1 (0.50) | CYP19A1CYP3A4KMT2ATSHRHIF1A | |
| Triphenylmethanol SCHEMBL700 | 0.84 | CYP19A1 (0.50) | CYP19A1CYP3A4KMT2ATSHRHIF1A | |
| Triphenylmethanol SCHEMBL1332873 | 0.84 | CYP19A1 (0.50) | CYP19A1CYP3A4KMT2ATSHRHIF1A | |
| SCHEMBL675338 | 0.83 | CYP3A4 (0.71) | CYP19A1CYP3A4CYP3A5MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6797694-B2 | TRIARYLMETHANE DERIVATIVES HAVING INHIBITORY ACTIVITY ON AN INTERMEDIATE CONDUCTANCE CALCIUM ION ACTIVATED POTASSIUM CHANNEL (IKCA) | POSEIDON PHARMACEUTICALS A/S (DK) | 2004-09-28 | — | — | US | claimed |
| EP-1447408-A1 | Amino acid loaded trityl alcohol resins, method of production of amino acid loaded trityl alcohol resins and therapeutics produced therewith | Rohm and Haas Company (US) | 2004-08-18 | — | — | EP | claimed |
| US-20040158037-A1 | Amino acid loaded trityl alcohol resins, method of production of amino acid loaded trityl alcohol resins and biologically active substances and therapeutics produced therewith | BOHLING JAMES CHARLES (US) | 2004-08-12 | — | — | US | claimed |
| US-20020065247-A1 | Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction | NEUROSEARCH A/S (DK) | 2002-05-30 | — | — | US | claimed |
| EP-1181016-A1 | CHEMICAL COMPOUNDS HAVING ION CHANNEL BLOCKING ACTIVITY FOR THE TREATMENT OFIMMUNE DYSFUNCTION | NEUROSEARCH A/S (DK) | 2002-02-27 | — | — | EP | claimed |
| WO-2000069439-A1 | CHEMICAL COMPOUNDS HAVING ION CHANNEL BLOCKING ACTIVITY FOR THE TREATMENT OF IMMUNE DYSFUNCTION | NEUROSEARCH A/S (DK) | 2000-11-23 | — | — | WO | claimed |
| CN-117630242-A | Method for separating and detecting impurity a in clotrimazole intermediate by high performance liquid chromatography | 重庆华邦制药有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-114394913-B | Synthetic method of oxime ether derivative | 山东农业大学 | 2023-02-03 | — | — | CN | disclosed |
| CN-114394913-A | Synthetic method of oxime ether derivative | 山东农业大学 | 2022-04-26 | — | — | CN | disclosed |
| WO-2017070536-A1 | METHODS AND AGENTS FOR TREATING DISEASES | ANGION BIOMEDICA CORP. (US) | 2017-04-27 | — | — | WO | disclosed |
| US-8026263-B2 | Methods for inhibiting neoproliferative changes in blood vessel walls | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026263-B2 | Methods for inhibiting neoproliferative changes in blood vessel walls | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026263-B2 | Methods for inhibiting neoproliferative changes in blood vessel walls | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-27 | — | — | US | disclosed |
| EP-1181016-A1 | CHEMICAL COMPOUNDS HAVING ION CHANNEL BLOCKING ACTIVITY FOR THE TREATMENT OFIMMUNE DYSFUNCTION | NEUROSEARCH A/S (DK) | 2002-02-27 | — | — | EP | disclosed |
| WO-2000069439-A1 | CHEMICAL COMPOUNDS HAVING ION CHANNEL BLOCKING ACTIVITY FOR THE TREATMENT OF IMMUNE DYSFUNCTION | NEUROSEARCH A/S (DK) | 2000-11-23 | — | — | WO | disclosed |
| EP-0703498-B1 | Photosensitive resin composition and method for forming a photoresist pattern | MITSUBISHI CHEM CORP (JP) | 1997-12-29 | — | — | EP | disclosed |
| US-5698362-A | CONTAINING A TRIARYLMETHANE DERIVATIVE; HIGH RESOLUTION, EXCELLENT IN DEPTH OF FOCUS AND PATTERN PROFILE, STORAGE STABLE | MITSUBISHI CHEMICAL CORPORATION (JP) | 1997-12-16 | — | — | US | disclosed |
| EP-0703498-A1 | Photosensitive resin composition and method for forming a photoresist pattern | MITSUBISHI CHEMICAL CORPORATION (JP) | 1996-03-27 | — | — | EP | disclosed |
| US-4116963-A | ANTIDIARRHEAL, CENTRAL NERVOUS SYSTEM PROPERTIES | G.D. SEARLE & CO. (US) | 1978-09-26 | — | — | US | disclosed |
| US-4072686-A | ANTIDIARRHEAL | G. D. SEARLE & CO. (US) | 1978-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065247-A1 | Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction | KCNN2, KCNN1, KCNN3 | CYP19A1 3855/4885CYP3A4 3082/4885CYP3A5 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.